Development of a red-shifted photosensitizer for near-infrared photoimmunotherapy of cancer

Near-infrared photoimmunotherapy (NIR-PIT) is a recently described method for cancer treatment that utilizes an antibody-conjugated phthalocyanine photosensitizer and NIR light. In NIR-PIT, light of 690 nm wavelength is used to activate a photosensitizer, IR700, while longer-wavelength light penetra...

Full description

Bibliographic Details
Main Authors: Yuto Goto, Kanta Ando, Hideo Takakura, Kohei Nakajima, Masato Kobayashi, Osamu Inanami, Tetsuya Taketsugu, Mikako Ogawa
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:Journal of Photochemistry and Photobiology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666469024000058
_version_ 1827318555462336512
author Yuto Goto
Kanta Ando
Hideo Takakura
Kohei Nakajima
Masato Kobayashi
Osamu Inanami
Tetsuya Taketsugu
Mikako Ogawa
author_facet Yuto Goto
Kanta Ando
Hideo Takakura
Kohei Nakajima
Masato Kobayashi
Osamu Inanami
Tetsuya Taketsugu
Mikako Ogawa
author_sort Yuto Goto
collection DOAJ
description Near-infrared photoimmunotherapy (NIR-PIT) is a recently described method for cancer treatment that utilizes an antibody-conjugated phthalocyanine photosensitizer and NIR light. In NIR-PIT, light of 690 nm wavelength is used to activate a photosensitizer, IR700, while longer-wavelength light penetrates deeper into tissues. Thus, more effective NIR-PIT would be achieved by using photosensitizers that are activated by longer-wavelength light. The absorption wavelength would be red-shifted by destabilizing the highest occupied molecular orbital (HOMO) energy level by introducing electron donating groups at the α positions of a phthalocyanine ring. In this study, we developed a red-shifted photosensitizer for NIR-PIT, KA800, whose absorption wavelength was red-shifted by the introduction of ethoxy groups to IR700. As intended, the absorption maximum of KA800 was red-shifted compared to IR700 by 84 nm. Although phototoxicity of the antibody-KA800 (Ab-KA800) conjugate was observed in cultured cancer cells, no therapeutic effect was observed in mice. This is because the cytotoxicity of Ab-KA800 was mainly due to singlet oxygen, which can be quenched by abundant antioxidants in vivo. KA800 had low reactivity with respect to axial ligand cleavage required for inducing cell death via aggregate formation, a unique cytotoxic mechanism in NIR-PIT. The axial ligand cleavage proceeds via the anion radical formation of the photosensitizer, and KA800 was found to be less likely to receive an electron than IR700. This may be due to the destabilization of the HOMO energy level of KA800. Therefore, our findings suggest that stabilizing the lowest unoccupied molecular orbital (LUMO) energy level would be better than destabilizing the HOMO energy level for developing a red-shifted photosensitizer for NIR-PIT.
first_indexed 2024-03-08T02:01:07Z
format Article
id doaj.art-ae9cc01e20ad480b866e264cba63e411
institution Directory Open Access Journal
issn 2666-4690
language English
last_indexed 2024-04-25T00:04:00Z
publishDate 2024-04-01
publisher Elsevier
record_format Article
series Journal of Photochemistry and Photobiology
spelling doaj.art-ae9cc01e20ad480b866e264cba63e4112024-03-14T06:16:12ZengElsevierJournal of Photochemistry and Photobiology2666-46902024-04-0120100230Development of a red-shifted photosensitizer for near-infrared photoimmunotherapy of cancerYuto Goto0Kanta Ando1Hideo Takakura2Kohei Nakajima3Masato Kobayashi4Osamu Inanami5Tetsuya Taketsugu6Mikako Ogawa7Laboratory of Bioanalysis and Molecular Imaging, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Hokkaido, JapanLaboratory of Bioanalysis and Molecular Imaging, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Hokkaido, JapanLaboratory of Bioanalysis and Molecular Imaging, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Hokkaido, JapanLaboratory of Bioanalysis and Molecular Imaging, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Hokkaido, JapanDepartment of Chemistry, Faculty of Science, Hokkaido University, Sapporo, Hokkaido, Japan; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Hokkaido, JapanFaculty of Veterinary Medicine, Hokkaido University, Sapporo, Hokkaido, JapanDepartment of Chemistry, Faculty of Science, Hokkaido University, Sapporo, Hokkaido, Japan; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Hokkaido, JapanLaboratory of Bioanalysis and Molecular Imaging, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Hokkaido, Japan; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Hokkaido, Japan; Corresponding author at: Laboratory of Bioanalysis and Molecular Imaging, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Hokkaido 060-0812, Japan.Near-infrared photoimmunotherapy (NIR-PIT) is a recently described method for cancer treatment that utilizes an antibody-conjugated phthalocyanine photosensitizer and NIR light. In NIR-PIT, light of 690 nm wavelength is used to activate a photosensitizer, IR700, while longer-wavelength light penetrates deeper into tissues. Thus, more effective NIR-PIT would be achieved by using photosensitizers that are activated by longer-wavelength light. The absorption wavelength would be red-shifted by destabilizing the highest occupied molecular orbital (HOMO) energy level by introducing electron donating groups at the α positions of a phthalocyanine ring. In this study, we developed a red-shifted photosensitizer for NIR-PIT, KA800, whose absorption wavelength was red-shifted by the introduction of ethoxy groups to IR700. As intended, the absorption maximum of KA800 was red-shifted compared to IR700 by 84 nm. Although phototoxicity of the antibody-KA800 (Ab-KA800) conjugate was observed in cultured cancer cells, no therapeutic effect was observed in mice. This is because the cytotoxicity of Ab-KA800 was mainly due to singlet oxygen, which can be quenched by abundant antioxidants in vivo. KA800 had low reactivity with respect to axial ligand cleavage required for inducing cell death via aggregate formation, a unique cytotoxic mechanism in NIR-PIT. The axial ligand cleavage proceeds via the anion radical formation of the photosensitizer, and KA800 was found to be less likely to receive an electron than IR700. This may be due to the destabilization of the HOMO energy level of KA800. Therefore, our findings suggest that stabilizing the lowest unoccupied molecular orbital (LUMO) energy level would be better than destabilizing the HOMO energy level for developing a red-shifted photosensitizer for NIR-PIT.http://www.sciencedirect.com/science/article/pii/S2666469024000058Antibody conjugateAxial ligandNear-infrared photoimmunotherapyPhotosensitizerRed shiftSilicon phthalocyanine
spellingShingle Yuto Goto
Kanta Ando
Hideo Takakura
Kohei Nakajima
Masato Kobayashi
Osamu Inanami
Tetsuya Taketsugu
Mikako Ogawa
Development of a red-shifted photosensitizer for near-infrared photoimmunotherapy of cancer
Journal of Photochemistry and Photobiology
Antibody conjugate
Axial ligand
Near-infrared photoimmunotherapy
Photosensitizer
Red shift
Silicon phthalocyanine
title Development of a red-shifted photosensitizer for near-infrared photoimmunotherapy of cancer
title_full Development of a red-shifted photosensitizer for near-infrared photoimmunotherapy of cancer
title_fullStr Development of a red-shifted photosensitizer for near-infrared photoimmunotherapy of cancer
title_full_unstemmed Development of a red-shifted photosensitizer for near-infrared photoimmunotherapy of cancer
title_short Development of a red-shifted photosensitizer for near-infrared photoimmunotherapy of cancer
title_sort development of a red shifted photosensitizer for near infrared photoimmunotherapy of cancer
topic Antibody conjugate
Axial ligand
Near-infrared photoimmunotherapy
Photosensitizer
Red shift
Silicon phthalocyanine
url http://www.sciencedirect.com/science/article/pii/S2666469024000058
work_keys_str_mv AT yutogoto developmentofaredshiftedphotosensitizerfornearinfraredphotoimmunotherapyofcancer
AT kantaando developmentofaredshiftedphotosensitizerfornearinfraredphotoimmunotherapyofcancer
AT hideotakakura developmentofaredshiftedphotosensitizerfornearinfraredphotoimmunotherapyofcancer
AT koheinakajima developmentofaredshiftedphotosensitizerfornearinfraredphotoimmunotherapyofcancer
AT masatokobayashi developmentofaredshiftedphotosensitizerfornearinfraredphotoimmunotherapyofcancer
AT osamuinanami developmentofaredshiftedphotosensitizerfornearinfraredphotoimmunotherapyofcancer
AT tetsuyataketsugu developmentofaredshiftedphotosensitizerfornearinfraredphotoimmunotherapyofcancer
AT mikakoogawa developmentofaredshiftedphotosensitizerfornearinfraredphotoimmunotherapyofcancer